Takeshi Okada Selected Research

(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acid

2/2022	Anti-GPIHBP1 Antibody-Positive Autoimmune Hyperchylomicronemia and Immune Thrombocytopenia.
1/2022	Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy.
9/2021	Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate.
10/2018	A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice.
2/2018	A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takeshi Okada Research Topics

Disease

17	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 01/2021 - 02/2017
8	Brain Edema (Cerebral Edema) 01/2021 - 11/2018
7	Brain Injuries (Brain Injury) 01/2021 - 02/2017
5	Neuroinflammatory Diseases 11/2020 - 02/2017
4	Cardiovascular Diseases (Cardiovascular Disease) 04/2022 - 01/2018
4	Cardiomyopathies (Cardiomyopathy) 01/2022 - 01/2013
4	Fibrosis (Cirrhosis) 01/2022 - 01/2013
4	Intracranial Vasospasm 01/2020 - 02/2017
3	Myocardial Infarction 02/2022 - 01/2013
3	Hypertriglyceridemia 02/2022 - 02/2018
3	Inflammation (Inflammations) 01/2020 - 10/2013
3	Rupture 01/2020 - 01/2016
3	Intracranial Aneurysm (Cerebral Aneurysm) 01/2020 - 01/2016
3	Heart Failure 10/2019 - 04/2011
3	Neoplasms (Cancer) 07/2019 - 01/2008
2	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 04/2022 - 07/2021
2	Edema (Dropsy) 10/2020 - 01/2020
2	Brain Ischemia (Cerebral Ischemia) 07/2020 - 10/2019
2	Cardiomegaly (Heart Hypertrophy) 01/2020 - 01/2019
2	Atherosclerosis 10/2019 - 10/2013
2	Cholesteryl Ester Transfer Protein Deficiency 03/2019 - 01/2018
2	Aneurysm (Aneurysms) 04/2016 - 01/2016
2	Hypertension (High Blood Pressure) 12/2012 - 12/2011
1	Platelet Glycoprotein IV Deficiency 04/2022
1	Coronary Artery Disease (Coronary Atherosclerosis) 04/2022
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 02/2022
1	Hypertrophy 01/2022
1	Fatty Liver 01/2022
1	Dyslipidemias (Dyslipidemia) 09/2021
1	Ischemic Stroke 01/2021
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021
1	Porcine Reproductive and Respiratory Syndrome (PRRS) 07/2020
1	Cerebral Infarction 01/2020
1	Stroke (Strokes) 01/2020
1	Muscle Spasticity (Spastic) 01/2020

Drug/Important Bio-Agent (IBA)

11	Proteins (Proteins, Gene)FDA Link 01/2021 - 10/2013
6	Toll-Like Receptor 4IBA 01/2020 - 02/2017
5	(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acidIBA 02/2022 - 02/2018
5	TenascinIBA 01/2020 - 11/2018
4	Mitogen-Activated Protein KinasesIBA 07/2020 - 02/2017
3	Lipoproteins (Lipoprotein)IBA 09/2021 - 01/2018
3	LigandsIBA 01/2020 - 02/2017
2	Adenosine Triphosphate (ATP)IBA 04/2022 - 01/2019
2	CholesterolIBA 01/2022 - 01/2020
2	Pharmaceutical PreparationsIBA 07/2021 - 03/2007
2	CytokinesIBA 11/2020 - 07/2020
2	Toll-Like Receptors (Toll-Like Receptor)IBA 07/2020 - 02/2017
2	Galectin 3 (LGALS3)IBA 01/2020 - 11/2018
2	ProgranulinsIBA 01/2020 - 10/2013
2	Cilostazol (Pletal)FDA LinkGeneric 01/2020 - 08/2014
2	ErbB Receptors (EGF Receptor)IBA 01/2020 - 07/2019
2	Complement System Proteins (Complement)IBA 01/2020 - 03/2019
2	Heme (Haem)IBA 01/2020 - 02/2017
2	NF-kappa B (NF-kB)IBA 01/2020 - 01/2020
2	Fibrinogen (Factor I)FDA Link 01/2020 - 02/2017
2	RivaroxabanIBA 10/2019 - 08/2014
2	Cholesterol Ester Transfer ProteinsIBA 03/2019 - 01/2018
1	oxidized low density lipoproteinIBA 04/2022
1	AcidsIBA 04/2022
1	CD36 AntigensIBA 04/2022
1	LDL CholesterolIBA 04/2022
1	SteroidsIBA 02/2022
1	Inosine Triphosphate (ITP)IBA 02/2022
1	InflammasomesIBA 01/2022
1	Probucol (Lorelco)FDA Link 07/2021
1	Small Interfering RNA (siRNA)IBA 01/2021
1	Matrix Metalloproteinases (MMPs)IBA 01/2021
1	Caspase 3 (Caspase-3)IBA 01/2021
1	bcl-2-Associated X Protein (bcl 2 Associated X Protein)IBA 01/2021
1	Interferon Regulatory FactorsIBA 01/2021
1	Liver X ReceptorsIBA 01/2021
1	IntegrinsIBA 01/2021
1	Type 1 Galanin ReceptorIBA 01/2021
1	T0901317IBA 01/2021
1	Immunoglobulin G (IgG)IBA 01/2021
1	Dynamin IIBA 01/2021
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 11/2020
1	Enhancer of Zeste Homolog 2 ProteinIBA 11/2020
1	Histones (Histone)IBA 11/2020
1	TNF Receptor-Associated Factor 6 (TRAF6)IBA 11/2020
1	Lysine (L-Lysine)FDA Link 11/2020
1	Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)IBA 10/2020
1	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 10/2020
1	Sulfonylurea ReceptorsIBA 10/2020
1	Adenosine Monophosphate (AMP)IBA 10/2020
1	Adenylyl Cyclases (Adenylyl Cyclase)IBA 10/2020
1	Pituitary Adenylate Cyclase-Activating Polypeptide ReceptorsIBA 10/2020
1	Biomarkers (Surrogate Marker)IBA 07/2020
1	NucleotidesIBA 07/2020
1	Advanced Glycation End ProductsIBA 07/2020
1	Pattern Recognition ReceptorsIBA 07/2020
1	ethyl 6- (N- (2- chloro- 4- fluorophenyl)sulfamoyl)cyclohex- 1- ene- 1- carboxylateIBA 01/2020
1	7-ketocholesterolIBA 01/2020
1	CaspasesIBA 01/2020
1	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2020
1	CateninsIBA 01/2020
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 12/2019

Therapy/Procedure

3	Therapeutics 02/2022 - 08/2014
3	Craniotomy 08/2013 - 01/2008
2	Ligation 10/2019 - 01/2013